This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://localhost/temp/predkladatel/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n11http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F10%3A00051508%21RIV12-MSM-14110___/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F10%3A00051508%21RIV12-MSM-14110___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer.
dcterms:title
Therapy of small cell lung cancer with emphasis on oral topotecan Therapy of small cell lung cancer with emphasis on oral topotecan
skos:prefLabel
Therapy of small cell lung cancer with emphasis on oral topotecan Therapy of small cell lung cancer with emphasis on oral topotecan
skos:notation
RIV/00216224:14110/10:00051508!RIV12-MSM-14110___
n3:aktivita
n14:I n14:V
n3:aktivity
I, V
n3:cisloPeriodika
1
n3:dodaniDat
n4:2012
n3:domaciTvurceVysledku
n12:2428245
n3:druhVysledku
n7:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
292688
n3:idVysledku
RIV/00216224:14110/10:00051508
n3:jazykVysledku
n9:eng
n3:klicovaSlova
Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan
n3:klicoveSlovo
n8:Second-line%20therapy n8:New%20drugs n8:Topotecan n8:Brain%20irradiation n8:Chemotherapy n8:Thoracic%20radiotherapy
n3:kodStatuVydavatele
IE - Irsko
n3:kontrolniKodProRIV
[75EA72309A21]
n3:nazevZdroje
Lung Cancer
n3:obor
n10:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
16
n3:rokUplatneniVysledku
n4:2010
n3:svazekPeriodika
70
n3:tvurceVysledku
Rooneem, R. Purkalne, G. Ostoros, G. Berzinec, Peter Zakotnik, B. Zwitter, M. Zielinski, Ch.C. Stanculeanu, D. Tzekova, V. Pirker, Robert Skřičková, Jana Plate, S. Kasan, P. Timcheva, C. Brincat, S. Pesek, M.
n3:wos
000282503700002
s:issn
0169-5002
s:numberOfPages
7
n11:doi
10.1016/j.lungcan.2010.05.020
n13:organizacniJednotka
14110